Ustekinumab associated with flares of psoriatic arthritis

Emily F. Stamell, Allison Kutner, Kate Viola, Steven R. Cohen

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Importance Ustekinumab is a human monoclonal antibody that binds to the shared p40 subunit of interleukin (IL) 12 and IL-23. It is approved in the United States for adults (18 years) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In 1 phase 2 trial of ustekinumab for treatment of psoriatic arthritis, joint disease improved. Observation We report 4 cases of ustekinumab monotherapy for plaque psoriasis that resulted in disabling flares of known psoriatic arthritis or unmasked previously occult joint disease. In all of our cases, psoriasis improved dramatically with ustekinumab therapy while psoriatic arthritis flared. Conclusions And Relevance Despite early results of a phase 2 ustekinumab trial suggesting efficacy for both plaque psoriasis and psoriatic arthritis, our case series raises concern that ustekinumab may unmask or aggravate joint disease in selected patients. These data underscore the need for further investigation of ustekinumab's effects on psoriatic arthritis.

Original languageEnglish (US)
Pages (from-to)1410-1413
Number of pages4
JournalJAMA Dermatology
Volume149
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Psoriatic Arthritis
Psoriasis
Joint Diseases
Interleukin-12 Subunit p40
Phototherapy
Ustekinumab
Therapeutics
Monoclonal Antibodies
Observation

ASJC Scopus subject areas

  • Dermatology

Cite this

Ustekinumab associated with flares of psoriatic arthritis. / Stamell, Emily F.; Kutner, Allison; Viola, Kate; Cohen, Steven R.

In: JAMA Dermatology, Vol. 149, No. 12, 12.2013, p. 1410-1413.

Research output: Contribution to journalArticle

Stamell, Emily F. ; Kutner, Allison ; Viola, Kate ; Cohen, Steven R. / Ustekinumab associated with flares of psoriatic arthritis. In: JAMA Dermatology. 2013 ; Vol. 149, No. 12. pp. 1410-1413.
@article{4f80d914b2194e0697c70707dec27c20,
title = "Ustekinumab associated with flares of psoriatic arthritis",
abstract = "Importance Ustekinumab is a human monoclonal antibody that binds to the shared p40 subunit of interleukin (IL) 12 and IL-23. It is approved in the United States for adults (18 years) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In 1 phase 2 trial of ustekinumab for treatment of psoriatic arthritis, joint disease improved. Observation We report 4 cases of ustekinumab monotherapy for plaque psoriasis that resulted in disabling flares of known psoriatic arthritis or unmasked previously occult joint disease. In all of our cases, psoriasis improved dramatically with ustekinumab therapy while psoriatic arthritis flared. Conclusions And Relevance Despite early results of a phase 2 ustekinumab trial suggesting efficacy for both plaque psoriasis and psoriatic arthritis, our case series raises concern that ustekinumab may unmask or aggravate joint disease in selected patients. These data underscore the need for further investigation of ustekinumab's effects on psoriatic arthritis.",
author = "Stamell, {Emily F.} and Allison Kutner and Kate Viola and Cohen, {Steven R.}",
year = "2013",
month = "12",
doi = "10.1001/jamadermatol.2013.5728",
language = "English (US)",
volume = "149",
pages = "1410--1413",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Ustekinumab associated with flares of psoriatic arthritis

AU - Stamell, Emily F.

AU - Kutner, Allison

AU - Viola, Kate

AU - Cohen, Steven R.

PY - 2013/12

Y1 - 2013/12

N2 - Importance Ustekinumab is a human monoclonal antibody that binds to the shared p40 subunit of interleukin (IL) 12 and IL-23. It is approved in the United States for adults (18 years) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In 1 phase 2 trial of ustekinumab for treatment of psoriatic arthritis, joint disease improved. Observation We report 4 cases of ustekinumab monotherapy for plaque psoriasis that resulted in disabling flares of known psoriatic arthritis or unmasked previously occult joint disease. In all of our cases, psoriasis improved dramatically with ustekinumab therapy while psoriatic arthritis flared. Conclusions And Relevance Despite early results of a phase 2 ustekinumab trial suggesting efficacy for both plaque psoriasis and psoriatic arthritis, our case series raises concern that ustekinumab may unmask or aggravate joint disease in selected patients. These data underscore the need for further investigation of ustekinumab's effects on psoriatic arthritis.

AB - Importance Ustekinumab is a human monoclonal antibody that binds to the shared p40 subunit of interleukin (IL) 12 and IL-23. It is approved in the United States for adults (18 years) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In 1 phase 2 trial of ustekinumab for treatment of psoriatic arthritis, joint disease improved. Observation We report 4 cases of ustekinumab monotherapy for plaque psoriasis that resulted in disabling flares of known psoriatic arthritis or unmasked previously occult joint disease. In all of our cases, psoriasis improved dramatically with ustekinumab therapy while psoriatic arthritis flared. Conclusions And Relevance Despite early results of a phase 2 ustekinumab trial suggesting efficacy for both plaque psoriasis and psoriatic arthritis, our case series raises concern that ustekinumab may unmask or aggravate joint disease in selected patients. These data underscore the need for further investigation of ustekinumab's effects on psoriatic arthritis.

UR - http://www.scopus.com/inward/record.url?scp=84892170359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892170359&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2013.5728

DO - 10.1001/jamadermatol.2013.5728

M3 - Article

VL - 149

SP - 1410

EP - 1413

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 12

ER -